Compounds > alpha-aminopyridine
Page last updated: 2024-08-21

alpha-aminopyridine and crizotinib

alpha-aminopyridine has been researched along with crizotinib in 50 studies

Research

Studies (50)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's29 (58.00)24.3611
2020's21 (42.00)2.80

Authors

AuthorsStudies
Nakagawa, T; Yano, S1
Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O1
Lam, JL; Smeal, T; Vicini, P; Wang, H; Yamazaki, S; Zou, HY1
Affolter, T; Appleman, V; Brooun, A; Charest, A; Deng, YL; Engstrom, LD; Falk, MD; Fantin, VR; Hu, W; Jiang, P; Johnson, TW; Lam, J; Lappin, PB; Li, Q; Liu, W; McDonnell, SR; McTigue, M; Nichols, T; Smeal, T; Timofeevski, S; West, M; Wong, KA; Zou, HY1
Ichinose, Y; Seto, T; Takenoyama, M; Toyokawa, G1
Infarinato, NR; Krytska, K; Lee, NV; Lemmon, MA; Li, Y; Mossé, YP; Park, JH; Ryles, HT; Sano, R; Smeal, T; Szigety, KM; Zou, HY1
Bergqvist, S; Brooun, A; Burke, BJ; Dardaei, L; Deng, YL; Engelman, JA; Frias, RL; Friboulet, L; Gainor, JF; Getz, G; Iafrate, AJ; James, LP; Johnson, TW; Katayama, R; Le, L; Leshchiner, I; Liu, W; Logan, J; McTigue, M; Schultz, KR; Shaw, AT; Smeal, T; Timofeevski, S1
André, F; Auger, N; Besse, B; Facchinetti, F; Farace, F; Friboulet, L; Kuo, MS; Lacroix, L; Loriot, Y; Mahjoubi, L; Planchard, D; Remon, J; Scoazec, JY; Soria, JC1
Chand, D; Chesler, L; Danielson, LS; El Wakil, A; Guan, J; Hallberg, B; Jamin, Y; Johnson, TW; Martinsson, T; Palmer, RH; Robinson, SP; Ruuth, K; Smeal, T; Tucker, ER; Umapathy, G; Wan, H; Witek, B1
Dhanasingh, I; Kanteti, R; Kindler, HL; Lennon, FE; Mambetsariev, B; Mirzapoiazova, T; Riehm, JJ; Salgia, R1
Bria, E; Brunelli, M; Caccese, M; Caliò, A; Carbognin, L; Cuppone, F; Ferrara, R; Grizzi, G; Petraglia, S; Pilotto, S; Scarpa, A; Tortora, G1
Chadha, N; Pathak, D; Silakari, O1
Ali, SM; Fernandez-Rocha, MY; Gitlitz, BJ; Lee, TK; Milliken, J; Ou, SI; Pavlick, D; Schrock, AB; Young, L; Zhu, VW1
Besse, B; Bria, E; Facchinetti, F; Friboulet, L; Minari, R; Rossi, G; Soria, JC; Tiseo, M1
Ma, MJ; Mekhail, TM; Parker, JV; Yuan, C1
Wan, S; Wang, Y; Wu, X; Zhang, J1
Hayashi, S; Hibino, Y; Kitada, M; Minami, Y; Miyokawa, N; Ohsaki, Y; Okumura, S; Sado, M; Sasaki, T; Yoshida, R1
Benes, CH; Damon, LJ; Dardaei, L; Dastur, A; Dicecca, R; Engelman, JA; Farago, AF; Fintelmann, FJ; Friboulet, L; Gainor, JF; Greenberg, M; Held, MA; Kattermann, KE; Kodack, DP; Lee, D; Niederst, MJ; Parks, M; Piotrowska, Z; Riley, AK; Rizzo, C; Sequist, LV; Shaw, AT; von Flotow, F1
Dong, L; Li, S; Xia, J; Zhang, J; Zhang, P; Zhang, X; Zhang, Y; Zhu, N1
Elkon, JM; Millett, RL; Tabbara, IA1
Camidge, DR; Honce, JM; Lindquist, DL; Sakamoto, MR1
Ekman, S; Hydbring, P; Jatta, K; Kacal, M; Kanony, M; Kis, L; Lai, Y; Lewensohn, R; Norberg, E; Stukan, I; Vakifahmetoglu-Norberg, H1
Bai, Y; Deng, L; Ding, M; Lu, D; Shao, YW; Wu, X; Yang, Y; Yu, R1
Buffoni, L; Pellerino, A; Rudà, R; Soffietti, R1
Chiba, S; Goto, K; Hatanaka, Y; Ikezawa, Y; Kitai, H; Matsumoto, S; Mizugaki, H; Sakakibara-Konishi, J; Sasaki, T; Shinagawa, N; Yoshida, R1
Compter, A; de Waard, Q; Gafer, H; van den Heuvel, M1
Higo, H; Hotta, K; Ichihara, E; Kano, H; Kayatani, H; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Matsubara, T; Ninomiya, K; Ninomiya, T; Nishii, K; Ohashi, K; Rai, K; Sato, A; Tabata, M; Takata, M; Tomida, S; Toyooka, S; Watanabe, H1
Fujita, N; Gong, B; Hanzawa, H; Hata, AN; Isoyama, T; Iwasaki, S; Kagoshima, Y; Kamai, Y; Katayama, R; Kiga, M; Koike, S; Miyamoto, M; Nakao, N; Nishio, M; Oh-Hara, T; Seto, Y; Shaw, AT; Shimizu, Y; Takeda, Y; Togashi, N; Tominaga, Y; Watanabe, K; Yanagitani, N; Yoda, S1
Chen, W; Guo, X; Ke, D; Yu, Y; Zhang, C; Zhang, G1
Fujita, N; Horiike, A; Katayama, R; Kitazono, S; Koike, S; Nishikawa, S; Nishio, M; Ohyanagi, F; Tambo, Y; Tsukahara, M; Uchibori, K; Yanagitani, N; Yoshizawa, T1
Dejust, S; El Farsaoui, K; Morland, D; Moubtakir, A; Prevost, A1
Bode-Lesniewska, B; Fritz, C; John, H; Pless, M; Reinhart, S; Trachsel, Y; Wagner, U1
Fujiwara, Y; Naito, T; Shiraishi, H1
Bauer, TM; Calella, AM; de Marinis, F; Felip, E; Goto, Y; Kim, DW; Liu, G; Mazieres, J; Mok, T; Peltz, G; Polli, A; Shaw, AT; Solomon, BJ; Thurm, H2
Eisenstein, M1
Romero, D1
Kuang, S; Leighl, NB1
Adachi, J; Araki, M; Friboulet, L; Fujita, N; Katayama, K; Katayama, R; Kukimoto-Niino, M; Kutkowska, J; Ma, B; Maruyama, K; Mizuta, H; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sagae, Y; Sasakura, Y; Shirouzu, M; Simizu, S; Takagi, S; Takemoto, A; Tamai, K; Watanabe, K; Yanagitani, N1
Li, H; Sun, Y; Wang, J; Xu, X1
He, X; Jiao, XD; Ling, Y; Liu, J; Liu, K; Qin, BD; Song, K; Wu, Y; Xu, AQ; Zang, YS1
Fukushima, T; Kanda, S; Kobayashi, T; Koizumi, T; Noguchi, T; Sekiguchi, N1
Chiang, CL; Chiang, TS; Chiu, CH; Chung, HP; Hung, JY; Ku, WH; Lee, KY; Lee, MH; Lin, CB; Lin, YT; Shih, JY; Su, J; Su, WC; Tseng, YH; Wei, YF; Wu, SY1
Bai, C; Chang, J; Chen, G; Cheng, Y; Cui, J; Du, Y; Fan, Y; Fang, J; Huang, C; Li, H; Li, J; Liu, X; Liu, Z; Lu, S; Lu, Y; Pan, H; Peltz, G; Song, Y; Wang, K; Wu, YL; Yang, N; Zhang, H; Zhang, K; Zhao, H; Zhou, J; Zhou, Q1
Baker, S; Blanchard, E; Brahmer, JR; Celano, P; Duma, N; Elkins, IB; Ellis, PM; Haddad, RY; Hesketh, PJ; Jain, D; Jaiyesimi, IA; Johnson, DH; Leighl, NB; Mamdani, H; Masters, G; Moffitt, PR; Phillips, T; Riely, GJ; Robinson, AG; Rosell, R; Schiller, JH; Schneider, BJ; Singh, N; Spigel, DR; Temin, S1
Du, D; Ji, J; Ma, H; Qiu, Y; Xie, B; Zhang, W; Zhou, J; Zhu, L1
Liu, Q; Luo, X; Peng, L; Zeng, X; Zhou, Z1
Bauer, TM; Felip, E; Goto, Y; Iadeluca, L; Jassem, J; K Mok, TS; Kim, DW; Liu, G; López, FL; Marinis, F; Mazieres, J; Messina, R; Polli, A; Shaw, AT; Solomon, BJ; Soo, RA; Toffalorio, F; Wu, YL1
Guo, F; Huang, C; Huang, Y; Jiang, Y; Liu, S; Tian, Y; Wan, S; Wu, G; Yu, Y; Zhang, J; Zhu, J; Zhu, Z1

Reviews

6 review(s) available for alpha-aminopyridine and crizotinib

ArticleYear
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
    Cancer metastasis reviews, 2015, Volume: 34, Issue:4

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Brain; Brain Neoplasms; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Organophosphorus Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones

2015
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:17

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Piperidines; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases

2016
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
    Cancer treatment reviews, 2017, Volume: 55

    Topics: Aminopyridines; Anilides; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Sulfones

2017
Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Anticancer research, 2018, Volume: 38, Issue:9

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Organophosphorus Compounds; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Small Molecule Libraries

2018
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
    Japanese journal of clinical oncology, 2021, Jan-01, Volume: 51, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines

2021
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
    Future oncology (London, England), 2023, Volume: 19, Issue:14

    Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors

2023

Trials

4 trial(s) available for alpha-aminopyridine and crizotinib

ArticleYear
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
    The New England journal of medicine, 2016, Jan-07, Volume: 374, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Female; Humans; Lactams; Lactams, Macrocyclic; Liver Failure; Liver Neoplasms; Lung Neoplasms; Middle Aged; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones

2016
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-15, Volume: 22, Issue:24

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones

2016
First-Line Lorlatinib or Crizotinib in Advanced
    The New England journal of medicine, 2020, 11-19, Volume: 383, Issue:21

    Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Hyperlipidemias; Intention to Treat Analysis; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation; Pyrazoles; Survival Analysis

2020
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2022, Volume: 17, Issue:6

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Crizotinib; Humans; Lactams; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Taiwan

2022

Other Studies

40 other study(ies) available for alpha-aminopyridine and crizotinib

ArticleYear
The current state of molecularly targeted drugs targeting HGF/Met.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:1

    Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2

2014
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
    Acta pharmaceutica Hungarica, 2013, Volume: 83, Issue:4

    Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines

2013
Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
    Drug metabolism and disposition: the biological fate of chemicals, 2015, Volume: 43, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Female; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Models, Biological; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays

2015
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
    Proceedings of the National Academy of Sciences of the United States of America, 2015, Mar-17, Volume: 112, Issue:11

    Topics: Aminopyridines; Animals; Carcinogenesis; Cell Proliferation; Crizotinib; Crystallography, X-Ray; Disease Models, Animal; Drug Resistance, Neoplasm; Glioma; Humans; Lactams; Lactams, Macrocyclic; Mice; Models, Molecular; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Signal Transduction

2015
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
    Cancer discovery, 2016, Volume: 6, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Mice; Mutation; Neuroblastoma; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays

2016
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
    Disease models & mechanisms, 2016, 09-01, Volume: 9, Issue:9

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Crizotinib; Lactams; Lactams, Macrocyclic; Mice, Inbred BALB C; Mice, Nude; Mutation; N-Myc Proto-Oncogene Protein; Neuroblastoma; PC12 Cells; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Rats; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays

2016
PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
    Scientific reports, 2016, 09-13, Volume: 6

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crizotinib; Drug Synergism; Female; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; Microtubules; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays

2016
Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
    Journal of molecular graphics & modelling, 2016, Volume: 70

    Topics: Aminopyridines; Crizotinib; Crystallography, X-Ray; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Solubility; Structure-Activity Relationship; User-Computer Interface

2016
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
    Lung cancer (Amsterdam, Netherlands), 2017, Volume: 106

    Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Crizotinib; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Lactams; Lactams, Macrocyclic; Liquid Biopsy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Retinoblastoma Binding Proteins; Small Cell Lung Carcinoma; Ubiquitin-Protein Ligases

2017
Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.
    The American journal of case reports, 2017, Jul-17, Volume: 18

    Topics: Adolescent; Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Crizotinib; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Meningeal Neoplasms; Myofibroblasts; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sarcoma; Sulfones

2017
Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
    Journal of biomolecular structure & dynamics, 2018, Volume: 36, Issue:12

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Energy Metabolism; Humans; Lactams; Lactams, Macrocyclic; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles

2018
Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer.
    International journal of oncology, 2017, Volume: 51, Issue:5

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Mice; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; src-Family Kinases; Sulfones; Xenograft Model Antitumor Assays

2017
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.
    Cell reports, 2017, Dec-12, Volume: 21, Issue:11

    Topics: Acrylamides; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Feeder Cells; Fluorescent Antibody Technique; Gene Expression; High-Throughput Screening Assays; Humans; Keratin-18; Keratin-8; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neoplasms; Piperazines; Precision Medicine; Primary Cell Culture; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured

2017
Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.
    BMC pulmonary medicine, 2018, Jan-23, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Crizotinib; Cytoskeletal Proteins; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Oncogene Fusion; Pemetrexed; Progression-Free Survival; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Time Factors

2018
Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
    Clinical lung cancer, 2019, Volume: 20, Issue:2

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System; Crizotinib; Drug Approval; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Neoplasm Metastasis; Organophosphorus Compounds; Pyrazoles; Pyrimidines; Recurrence; Treatment Outcome

2019
miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Biochemical and biophysical research communications, 2019, 04-02, Volume: 511, Issue:2

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; MicroRNAs; Microtubule-Associated Proteins; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Serine Endopeptidases

2019
Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.
    Clinical lung cancer, 2019, Volume: 20, Issue:3

    Topics: Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Liquid Biopsy; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines

2019
Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors.
    Neurology, 2019, 07-30, Volume: 93, Issue:5

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Spinal Cord Neoplasms; Sulfones; Treatment Outcome

2019
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer.
    Clinical lung cancer, 2019, Volume: 20, Issue:5

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Treatment Outcome

2019
Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases.
    BMJ case reports, 2019, Jul-24, Volume: 12, Issue:7

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Progression-Free Survival; Pyrazoles; Remission Induction; Treatment Outcome

2019
Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High Tumor Mutation Burden.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019, Volume: 14, Issue:11

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Lactams; Lactams, Macrocyclic; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Middle Aged; Mutation; Piperidines; Pyrazoles; Xenograft Model Antitumor Assays

2019
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
    Nature communications, 2019, 08-09, Volume: 10, Issue:1

    Topics: Aminopyridines; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Development; Drug Resistance, Neoplasm; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Membrane Glycoproteins; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Receptor, trkB

2019
Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants.
    European journal of medicinal chemistry, 2019, Dec-01, Volume: 183

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Humans; Mutation; Protein Kinase Inhibitors; Pyridones

2019
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
    Cancer science, 2020, Volume: 111, Issue:3

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Asian People; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recombinant Proteins; Sulfones

2020
18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1-Positive Non-Small Cell Lung Cancer.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:3

    Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Crizotinib; Fluorodeoxyglucose F18; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Pyrazoles; Radiopharmaceuticals

2020
Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
    Urology, 2020, Volume: 146

    Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; Cystoscopy; Female; Fibronectins; Gene Fusion; Humans; Inflammation; Lactams; Myofibroblasts; Neoplasms, Muscle Tissue; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Treatment Outcome; Urinary Bladder Neoplasms

2020
New lung-cancer drugs extend survival times.
    Nature, 2020, Volume: 587, Issue:7834

    Topics: Acrylamides; Afatinib; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Hope; Humans; Lactams; Lung; Lung Neoplasms; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Quinazolinones; Survival Analysis

2020
Lorlatinib CROWNed.
    Nature reviews. Clinical oncology, 2021, Volume: 18, Issue:1

    Topics: Aminopyridines; Crizotinib; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles; Receptor Protein-Tyrosine Kinases

2021
Lorlatinib Outperforms Crizotinib in NSCLC.
    Cancer discovery, 2021, Volume: 11, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles

2021
Lorlatinib in ALK-Rearranged Lung Cancer.
    Cancer cell, 2021, 01-11, Volume: 39, Issue:1

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Crizotinib; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles

2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
    Nature communications, 2021, 02-24, Volume: 12, Issue:1

    Topics: Aminopyridines; Aniline Compounds; Animals; Apoptosis; Benzamides; Carbazoles; Cell Line; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Immunoblotting; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasm Recurrence, Local; Piperidines; Proto-Oncogene Proteins; Pyrazines; Pyrazoles; Receptor Protein-Tyrosine Kinases

2021
[A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors 
and Chemotherapy].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2021, May-20, Volume: 24, Issue:5

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Crizotinib; Female; Humans; Lactams; Lung Neoplasms; Microtubule-Associated Proteins; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Serine Endopeptidases; Sulfones

2021
Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report.
    JCO precision oncology, 2021, Volume: 5

    Topics: Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Colorectal Neoplasms; Crizotinib; Female; Gene Rearrangement; Humans; Lactams; Neoplasm Metastasis; Piperidines; Pyrazoles; Treatment Outcome

2021
Response to lorlatinib on a patient with ALK-rearranged non-small cell lung cancer harboring 1151Tins mutation with uterine metastasis.
    Thoracic cancer, 2021, Volume: 12, Issue:16

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Gene Rearrangement; Humans; Lactams; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Uterine Neoplasms

2021
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 156

    Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Crizotinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Factors; Sulfones; Taiwan; Treatment Outcome

2021
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
    Future oncology (London, England), 2021, Dec-01, Volume: 17, Issue:34

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Language; Lung Neoplasms; Pyrazoles

2021
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 10-01, Volume: 40, Issue:28

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Lung Neoplasms; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines

2022
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022, Volume: 24, Issue:11

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line; Cisplatin; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Microtubule Proteins; Mutation; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Tumor Suppressor Protein p53

2022
Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
    Frontiers in public health, 2022, Volume: 10

    Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Crizotinib; Humans; Lactams; Lung Neoplasms; Network Meta-Analysis; Organophosphorus Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyrimidines; Sulfones

2022
Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1
    Journal of enzyme inhibition and medicinal chemistry, 2023, Volume: 38, Issue:1

    Topics: Anaplastic Lymphoma Kinase; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins

2023